145 related articles for article (PubMed ID: 186417)
1. Immunological monitoring and immunotherapy in carcinoma of the lung.
Weese JL; Herberman RB; Perlin E; Mills M; Heims W; Blom J; Green D; Reid J; Bellinger S; Law I; McCoy JL; Dean JH; Cannon GB; Djeu J
Int J Cancer; 1976 Dec; 18(6):739-49. PubMed ID: 186417
[TBL] [Abstract][Full Text] [Related]
2. Combined-modality treatment of inoperable lung cancer (i.v. immunotherapy, chemotherapy, and radiotherapy).
Robinson E; Haim N; Segal R; Veseley Z; Mekori T
Cancer Treat Rep; 1985 Mar; 69(3):251-8. PubMed ID: 2983892
[TBL] [Abstract][Full Text] [Related]
3. Immune status in lung cancer: effects of BCG immunotherapy.
Gross NJ; Eddie-Quartey AC
Am Rev Respir Dis; 1976 Apr; 113(4):457-64. PubMed ID: 178255
[TBL] [Abstract][Full Text] [Related]
4. [Role of immunotherapy in the combined treatment of lung cancer].
Trapeznikov NN; Gorodilova VV; Babakova SV; Kadagidze ZG; Trakhtenberg AKh
Vopr Onkol; 1982; 28(2):51-6. PubMed ID: 6278769
[No Abstract] [Full Text] [Related]
5. Effects of combined immunotherapy with levamisole and Bacillus Calmette-Guérin on immunocompetence of patients with squamous cell carcinoma of the cervix, head and neck, and lung undergoing radiation therapy.
Olkowski ZL; McLaren JR; Skeen MJ
Cancer Treat Rep; 1978 Nov; 62(11):1651-61. PubMed ID: 310339
[TBL] [Abstract][Full Text] [Related]
6. Immunological evaluation of CTL precursor-oriented vaccines for advanced lung cancer patients.
Mine T; Gouhara R; Hida N; Imai N; Azuma K; Rikimaru T; Katagiri K; Nishikori M; Sukehiro A; Nakagawa M; Yamada A; Aizawa H; Shirouzu K; Itoh K; Yamana H
Cancer Sci; 2003 Jun; 94(6):548-56. PubMed ID: 12824881
[TBL] [Abstract][Full Text] [Related]
7. Non-specific immunostimulation in bronchogenic cancer.
Israel L
Scand J Respir Dis Suppl; 1974; 89():95-105. PubMed ID: 4370224
[No Abstract] [Full Text] [Related]
8. Extended survival observed in adoptive activated T lymphocyte immunotherapy for advanced lung cancer: results of a multicenter historical cohort study.
Iwai K; Soejima K; Kudoh S; Umezato Y; Kaneko T; Yoshimori K; Tokuda H; Yamaguchi T; Mizoo A; Setoguchi Y; Kamigaki T; Fujimoto K; Goto S
Cancer Immunol Immunother; 2012 Oct; 61(10):1781-90. PubMed ID: 22422103
[TBL] [Abstract][Full Text] [Related]
9. Immune evaluation of lung cancer patients undergoing radiation therapy.
Stefani S; Kerman R; Abbate J
Cancer; 1976 Jun; 37(6):2792-6. PubMed ID: 181124
[TBL] [Abstract][Full Text] [Related]
10. ["Active" rosettes and skin tests to recall antigens and phytohemagglutinin in 48 patients with non metastatic squamous cell lung carcinoma and before treatment (author's transl)].
Lang JM; Pauli G; Roeslin N; Bigel P; Bessot JC
Rev Fr Mal Respir; 1980; 8(1):11-6. PubMed ID: 6970392
[TBL] [Abstract][Full Text] [Related]
11. [Immunological monitoring of patients with carcinoma of the lung. Study method and preliminary research].
Banna P; Stivala F; Murabito R; Cordopatri F; Saggio A; Mosca F; Cinà C
Chir Ital; 1979 Dec; 31(6):1297-1313. PubMed ID: 233422
[TBL] [Abstract][Full Text] [Related]
12. HM1.24 (CD317) is a novel target against lung cancer for immunotherapy using anti-HM1.24 antibody.
Wang W; Nishioka Y; Ozaki S; Jalili A; Abe S; Kakiuchi S; Kishuku M; Minakuchi K; Matsumoto T; Sone S
Cancer Immunol Immunother; 2009 Jun; 58(6):967-76. PubMed ID: 18979097
[TBL] [Abstract][Full Text] [Related]
13. Immunologic status in lung cancer.
Brugarolas A; Takita H
Chest; 1973 Oct; 64(4):427-30. PubMed ID: 4355273
[No Abstract] [Full Text] [Related]
14. Depression of T lymphocyte response by non-T suppressor cells in lung cancer patients: a possible prognostic value of suppressor-cell activity.
Han T; Takita H
Cancer; 1979 Dec; 44(6):2090-8. PubMed ID: 228835
[No Abstract] [Full Text] [Related]
15. Immunologic alterations and active aspecific immunotherapy in lung cancer patients.
Banna P; Murabito R; Saggio A; Cordopatri F; Riggi M; Campo ME; Cinà C; Latteri S
Ital J Surg Sci; 1983; 13(2):133-7. PubMed ID: 6195126
[TBL] [Abstract][Full Text] [Related]
16. Effect of BCG cell-wall skeleton immunotherapy on the peripheral blood lymphocytes in patients with lung cancer after radiotherapy.
Nishikawa H; Yasaki S; Yoshimoto T; Sakatani M; Itoh M; Masuno T; Namba M; Ogura T; Hirao F; Azuma I; Yamamura Y
Gan; 1978 Dec; 69(6):819-24. PubMed ID: 750274
[TBL] [Abstract][Full Text] [Related]
17. Delayed cutaneous hypersensitivity and peripheral lymphocyte counts in patients with advanced cancer.
Lee YT; Sparks FC; Eilber FR; Morton DL
Cancer; 1975 Mar; 35(3):748-55. PubMed ID: 1111942
[TBL] [Abstract][Full Text] [Related]
18. [Immune status of patients with bronchial cancer].
Aulenbacher P; Manke HG; Drings P
Klin Wochenschr; 1987 May; 65(10):445-52. PubMed ID: 3037180
[TBL] [Abstract][Full Text] [Related]
19. Skin test in bronchogenic carcinoma. I. Correlation of the immunological status and the extent of the disease.
Takita H; Brugarolas A
J Surg Oncol; 1973; 5(4):315-8. PubMed ID: 4355620
[No Abstract] [Full Text] [Related]
20. In vitro evidence for increased cellular immunity to lung cancer antigen during Levamisole immunotherapy.
Urist MM; Boddie AW; Townsend CM; Holmes EC
J Thorac Cardiovasc Surg; 1977 Feb; 73(2):189-94. PubMed ID: 834057
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
